Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals
Authors:
- 24 October 2025
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 42 (12) , 1-24
Abstract
Glioblastoma (GBM), the most aggressive type of primary brain tumor in adults, is characterized by a poor prognosis and considerable resistance to current therapies. Traditional treatment approaches—surgery, radiation, and chemotherapy—offer few clinical benefits and are often linked to increased recurrence rates and significant adverse effects. This underscores the urgent need for novel therapeutic strategies. Targeting the transforming growth factor-beta (TGF-β) signaling pathway is a viable strategy. TGF-β acts as a tumor suppressor during the first stages of cancer but promotes tumor progression, angiogenesis, immune evasion, and the creation of an immunosuppressive tumor microenvironment in GBM. The deregulation of TGF-β signaling has been shown to interact with essential carcinogenic pathways, including the Wnt/β-catenin, PI3K/AKT, and Notch pathways, therefore aggravating GBM pathogenesis. TGF-β plays a pivotal role in controlling glioma stem cells and influencing the permeability of the blood–brain barrier, making it an attractive target for therapeutic intervention. Novel treatment approaches, including small-molecule inhibitors and monoclonal antibodies, as well as the use of phytochemicals such as flavonoids, quercetin, and other phytochemicals targeting specific elements of the TGF-β signaling pathway, have shown encouraging results in preclinical investigations and early-stage clinical trials. These novel strategies may enhance clinical outcomes and mitigate treatment limitations in GBM therapy by leveraging this system’s combined tumor-suppressive and immune-regulatory properties.Keywords
This publication has 160 references indexed in Scilit:
- Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS–reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico predictionMolecular and Cellular Biochemistry, 2020
- Berberine reversed the epithelial‐mesenchymal transition of normal colonic epithelial cells induced by SW480 cells through regulating the important components in the TGF‐β pathwayJournal of Cellular Physiology, 2018
- Astragaloside IV inhibits TGF‐β1‐induced epithelial‐mesenchymal transition through inhibition of the PI3K/Akt/NF‐κB pathway in gastric cancer cellsPhytotherapy Research, 2018
- Anthocyanidins inhibit epithelial–mesenchymal transition through a TGFβ/Smad2 signaling pathway in glioblastoma cellsMolecular Carcinogenesis, 2016
- TGF-β1 mediates the radiation response of prostate cancerJournal of Molecular Medicine, 2014
- TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancerClinical & Experimental Metastasis, 2013
- Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF‐A and TGFβ2 in vascular abnormalizationThe Journal of Pathology, 2012
- Flavonoids inhibit angiogenic cytokine production by human glioma cellsPhytotherapy Research, 2010
- The flavonoid rutin induces astrocyte and microglia activation and regulates TNF-alpha and NO release in primary glial cell culturesCell Biology and Toxicology, 2007
- Transforming growth factor‐β2 down‐regulates HLA‐DR antigen expression on human malignant glioma cells.European Journal of Immunology, 1988